The U.S. asthma therapy market has long been dominated by several effective and well-established treatments, including inhaled and oral therapies, but following the recent approval of two biologics with novel mechanisms of action and with several more biologics in late-stage development for asthma, this market is set to undergo substantial change. Indeed, the influx of costly new biologics and the onset of generic competition, including biosimilars, will make prescribers’ choice of therapy and payer decisions on reimbursement more and more complex. Marketers will struggle to gain favorable formulary position and physician uptake, while health plans try to contain drug-related healthcare spend. In Asthma | Access & Reimbursement | US, we present key insights from U.S. physicians and payers on the prescribing and reimbursement of current asthma therapies, and we explore the reimbursement dynamics that promote or restrict market access of current and emerging agents.


Related Reports

Asthma | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis - Adult Asthma (US)

Adult asthma is treated using two types of pharmacotherapy: rescue therapy to treat acute symptoms via bronchodilation (e.g., a SABA) and maintenance therapy to prevent exacerbations by targeting...

View Details

Asthma | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis - Pediatric Asthma (US)

Pediatric asthma is treated using two types of pharmacotherapies: rescue therapy for acute symptoms via bronchodilation (e.g., a SABA) and maintenance therapy to prevent exacerbations by targetin...

View Details

Asthma | Emerging Therapies | Dupixent (Dupilumab) (US) Wave 3

Dupixent (Sanofi / Regeneron), a first-in-class biologic that inhibits IL-4 / IL-13 signaling, was approved for the treatment of...

View Details

Asthma | Landscape & Forecast | Disease Landscape & Forecast

The asthma market consists of many well-established therapies, including inhaled agents (e.g., GlaxoSmithKline’s Advair / Seretide, AstraZeneca’s Symbicort, Boehringer Ingelheim&rsquo...

View Details